Search Results

BACK FACT-An English Downloads Download PDF Download DOC

FACT-Lym Functional Assessment of Cancer Therapy – Lymphoma For patients with Lymphoma (NHL) LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACT-Lym measure: MEASURE NAME: Functional Assessment of Cancer Therapy – Lymphoma (FACT-Lym) VERSION: 4 NUMBER OF ITEMS: 42 PATIENT POPULATION: Lymphoma patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Lymphoma Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: NFLymSI-18 , FACT-Leu , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Lym can be obtained by registering for permission. Users are not permitted to translate the FACT-Lym without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Lym may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Hlubocky, F., Webster, K., Cashy, J., Beaumont, J., & Cella, D. The development and validation of a measure of health-related quality of life for non-hodgkin’s lymphoma: the functional assessment of cancer therapy—lymphoma (FACT-Lym). Lymphoma 2013; Article ID 147176. doi: 10.1155/2013/147176. Hlubocky, F., Webster, K., Beaumont, J., Cashy, J., Paul, D., Abernathy, A., Syrjala, K., Von Roenn, J., & Cella, D. A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Lymphoma Symptom Index. Leukemia & Lymphoma 2013; 54(9): 1942-1946. doi: 10.3109/10428194.2012.76297. Pettengell, R., Donatti, C., Hoskin, P., Poynton, C., Kettle, P., Hancock, B., Johnson, S., Dyer, M., Rule, S., Walker, M., & Wild, D. The impact of follicular lymphoma on health-related quality of life. Annals of Oncology 2008; 19: 570–576. doi: 10.1093/annonc/mdm543. Cheson B.D., Trask P.C., Gribben J.G., et al. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Ann Hematol. 2017;96(2):253-259. doi:10.1007/s00277-016-2878-5. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures NFLymSI-18 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index - 18 Item Version LEARN MORE FACT-Leu Functional Assessment of Cancer Therapy – Leukemia LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

FACIT-Sp-12 Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale The 12-item Spiritual Well-Being Scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FACIT-Sp-12 measure: MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being 12 Item Scale (FACIT-Sp-12) VERSION: 4 NUMBER OF ITEMS: 12 PATIENT POPULATION: Patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Spiritual Well-Being, Meaning, Peace, Faith TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACIT-Sp , FACIT-Sp-Ex , FACIT-Pal DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-Sp-12 can be obtained by registering for permission. Users are not permitted to translate the FACIT-Sp-12 without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-Sp-12 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bormann, J., Aschbacher, K., Wetherell, J., Roesch, S., & Redwine., L. Effects of faith/assurance on cortisol levels are enhanced by a spiritual mantram intervention in adults with HIV: A randomized trial. Journal of Psychosomatic Research 2009; 66: 161–171. doi: 10.1016/j.jpsychores.2008.09.017. Bormann, J., Gifford, A., Shively, M., Smith, T., Redwine, L., Kelly, A., Becker, S., Gershwin, M., Bone, P., & Belding, W. Effects of Spiritual Mantram Repetition on HIV Outcomes: A Randomized Controlled Trial. Journal of Behavioral Medicine 2006; 29(4): 359-376. doi: 10.1007/s10865-006-9063-6. Brady, M.J., Peterman, A.H., Fitchett, G., Mo, M., & Cella, D. A case for including spirituality in quality of life measurement in oncology. Psycho-Oncology 1999; 8: 417-428. Bredle, J., Salsman, J., Debb, S., Arnold, B., & Cella, D. Spiritual Well-Being as a component of health-related quality of life: the functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp). Religions 2011; 2(1): 77-94. doi: 10.3390/rel2010077. Canada, A, Murphy, P., Fitchett, G., Peterman, A., & Schover, L. A 3-factor model for the FACIT-Sp. Psycho-Oncology 2008; 17: 908–916. doi: 10.1002/pon.1307. Cotton, S., Levine, E., Fitzpatrick, C., Dold, K, & Targ, E. Exploring the relationships among spiritual well-being, quality of life, and psychological adjustment in women with breast cancer. Psycho-Oncology 1999; 8: 429–438. Dapueto, J., Servente, L., Francolino, C., & Hahn, E. Determinants of Quality of Life in Patients with Cancer: A South American Study. Cancer 2005; 103(5): 1072-1081. doi: 10.1002/cncr.20870. Edmondson, D., Park, C., Blank, T., Fenster, J., & Mills, M. Deconstructing spiritual well-being: existential well-being and HRQOL in cancer survivors. Psycho-Oncology 2008; 17: 161–169. doi: 10.1002/pon.1197. Fradelos, E., Tzavella, F., Koukia, E., Tsaras, K., Papathanasiou, I., Aroni, A., Alikari, V., Ralli, M., Bredle, J., & Zyga1, S. The translation, validation and cultural adaptation of functional assessment of chronic illness therapy – spiritual well-being 12 (FACIT-SP12) scale in Greek language. Mater Sociomed 2016; 28(3): 229-234. doi: 10.5455/msm.2016.28.229-234. Jarafi, N., Zamani, A., Lazenby, M., Farajzadegan, Z., Emami, H., & Loghmani, A. Translation and validation of the Persian version of the functional assessment of chronic illness therapy—Spiritual well-being scale (FACIT-Sp) among Muslim Iranians in treatment for cancer. Palliative and Supportive Care 2013; 11: 29–35. doi:10.1017/S1478951512000727. Kahraman, B.N., Pehlivan, S. The effect of spiritual well-being on illness perception of lung cancer patıents. Support Care Cancer 31 , 107 (2023). https://doi.org/10.1007/s00520-022-07527-z Krupski, T., Kwan, L., Fink, A., Sonn, G., Maliski, S., & Litwin, M. Spirituality Influences Health Related Quality of Life in Men with Prostate Cancer. Psycho-Oncology 2006; 15: 121–131. doi: 10.1002/pon.929. Lazenby, M., Khatib, J., 2, Al-Khair, F., & Neamat, M. Psychometric properties of the Functional Assessment of Chronic Illness Therapy—Spiritual Well-being (FACIT-Sp) in an Arabic-speaking, predominantly Muslim population. Psycho-Oncology 2011; 22(1): 220-227. doi: 10.1002/pon.2062. McClain, C., Rosenfeld, B., & Breitbart, W. Effect of spiritual well-being on end-of-life despair in terminally-ill cancer patients. The Lancet 2003; 361: 1603-1607. McClain-Jacobson, C., Rosenfeld, B., Rosenfeld, B., Kosinski, A., Pessin, H., Cimino, J., & Breitbart, W. Belief in an afterlife, spiritual well-being and end-of-life despair in patients with advanced cancer. General Hospital Psychiatry 2004; 26: 484-486. doi: 10.1016/j.genhosppsych. Machul M, Bredle J, Jurek K, Dobrowolska B. Psychometric Properties of the Polish Version of the FACIT-Sp-12: Assessing Spiritual Well-Being Among Patients with Chronic Diseases. Med Sci Monit. 2023 Nov 16;29:e941769. doi: 10.12659/MSM.941769. PMID: 37968895; PMCID: PMC10662162. Morgan, P., Gaston-Johansson, F., & Mock, V. Spiritual Well-Being, Religious Coping, and the Quality of Life of African American Breast Cancer Treatment: A Pilot Study. The ABNF Journal 2006; 73-77. Murphy, P., Canada, A., Fitchett, G., Stein, K., Portier, K., Crammer, C., & Peterman, A. An examination of the 3-factor model and structural invariance across racial/ethnic groups for the FACIT-Sp: a report from the American Cancer Society’s Study of Cancer Survivors-II (SCS-II). Psycho-Oncology 2010; 19: 264–272. doi: 10.1002/pon.1559. Perkins, E., Small, B., Balducci, L., Extermann, M., Robb, C., & Haley, W. Individual differences in well-being in older breast cancer survivors. Critical Reviews in Oncology/Hematology 2007; 62: 74-83. doi: 10.1016/j.critrevonc.2006.11.002. Peterman, A., Fitchett, G., Brady, M., & Hernandez, L. Measuring Spiritual Well-Being in People With Cancer: The Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being Scale (FACIT-Sp). Annals of Behavioral Medicine 2002; 24(1):49–58. Rodin, G., Zimmermann, C., Rydall, A., Jones, J., Shepherd, A., Moore, M., Fruh, M., Donner, A., Gagliese, L. The Desire for Hastened Death in Patients with Metastatic Cancer. Journal of Pain and Symptom Management 2007; 33(6): 661-674. doi: 10.1016/j.jpainsymman. Rodin, G., Lo, C., Mikulincer, M., Donner, A., Gagliese, L., & Zimmermann, C. Pathways to distress: The multiple determinants of depression, hopelessness, and the desire for hasted death in metastatic cancer patients. Social Science & Medicine 2008; 68: 562–569. doi: 10.1016/j.socscimed. Schnoll, R., Harlow, L., & Brower, L. Spirituality, Demographic, and Disease Factors, and Adjustment to Cancer. Cancer Practice 2000; 8(6): 298-304. Stefanek, M., McDonald, P., & Hess, S. Religion, Spirituality and Cancer: Current Status and Methodological Challenges. Psycho-Oncology 2005; 14: 450–463. doi: 10.1002/pon.861. Stojković, S. & Prlić, N. Effect of faith on the acceptance of chronic disease patients. South Eastern Europe Health Sciences Journal 2012; 2(1): 52-61. Tate, D. & Forchheimer, M. Quality of Life, Life Satisfaction, and Spirituality: Comparing Outcomes Between Rehabilitation and Cancer Patients. American Journal of Physical Medicine & Rehabilitation 2002; 81(6): 400-410. Trevino, K., Pargament, K., Cotton, S., Leonard. A., Hahn, J., Caprini-Faigin, C., & Tsevat, J. Religious Coping and Physiological, Psychological, Social, and Spiritual Outcomes in Patients with HIV/AIDS: Cross-sectional and Longitudinal Findings. AIDS and Behavior 2010; 14: 379-389. doi: 10.1007/s10461-007-9332-6. Visser, A., Garssen, B., & Vingerhoets, A. Spirituality and well-being in cancer patients: a review. Psycho-Oncology 2010; 19: 565–572. doi: 10.1002/pon. Zavala, M., Maliski, S., Kwan, L., Fink, A., & Litwin, M. Spirituality and quality of life in low-income men with metastatic prostate cancer. Psycho-Oncology 2009; 18: 753–761. doi: 10.1002/pon.1460. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Sp Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being LEARN MORE FACIT-Sp-Ex Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being Expanded Version LEARN MORE FACIT-Pal Functional Assessment of Chronic Illness Therapy - Palliative Care LEARN MORE

FKSI-10 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version For patients with Kidney Cancer, a 10 item scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FKSI-10 measure: MEASURE NAME: Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version (FKSI-10) VERSION: 4 NUMBER OF ITEMS: 10 PATIENT POPULATION: Kidney cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Kidney cancer symptom index TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores available. RELATED MEASURES: FKSI-15 , NFKSI-19 , FKSI-DRS DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FKSI-10 can be obtained by registering for permission. Users are not permitted to translate the FKSI-10 without permission from FACIT.org. Permission from FACIT.org to translate the FKSI-10 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bukowski, R., Cella, D., Gondek, K., Escudier, B. Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer. American Journal of Clinical Oncology; 2007: 30(3): 220-227. doi: 10.1097/01.coc.0000258732.80710.05. Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Yount, S., Du, H., Dhanda, R., Gondek, K., Langefeld, K., George, J., Bro, W., Kelly, C., & Bukowski, R. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). Journal of Supportive Oncology 2006; 4(4):191-199. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FKSI-15 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version LEARN MORE NFKSI-19 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version LEARN MORE FKSI-DRS Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms LEARN MORE

PROMIS SF v1.0-Dyspnea-Functional Limitations 5b Patient Reported Outcomes Measurement Information System - Short Form - Dyspnea-Functional Limitations 5b For patients with dyspnea LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The PROMIS SF v1.0 – Dyspnea-Functional Limitations 5b includes 5 items from part II of the FACIT-Dyspnea adopted by the PROMIS Health Organization. MEASURE NAME: Patient Reported Outcomes Measurement Information System - Short Form - Dyspnea-Functional Limitations 5b VERSION: 1 NUMBER OF ITEMS: 5 PATIENT POPULATION: Dyspnea patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 4 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Functional Limitations TIME FOR COMPLETION: Less than 5 minutes SCORING: PROMIS Scoring Service: http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions RELATED MEASURES: FACIT-Dyspnea , PROMIS SF v1.0 – Dyspnea-Severity 10a , PROMIS SF v1.0 – Dyspnea-Severity 5b DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PROMIS-SF-v1.0-Dyspnea-Functional Limitations 5b can be obtained by registering for permission. Users are not permitted to translate the PROMIS-SF-v1.0-Dyspnea-Functional Limitations 5b without permission from FACIT.org. Permission from FACIT.org to translate the PROMIS-SF-v1.0-Dyspnea-Functional Limitations 5b may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Choi, S., Victorson, D., Yount, S., Anton, S., & Cella, D. Development of a conceptual framework and calibrated item banks to measure patient reported dyspnea severity and related functional limitations. Value in Health 2011; 14: 291-306. Ruo, B., Choi, S., Baker, D., Grady, K., & Cella,D. Development and validation of a computer adaptive test measuring dyspnea in heart failure. Journal of Cardiac Failure 2010; 16(8): 659-668. doi: 10.1016/j.cardfail.2010.03.002. Victorson, D., Anton, S., Hamilton, A., Yount, S., & Cella, D. A conceptual model of the experience of dyspnea and functional limitations in COPD. Value in Health 2009; 12(6): 1018-1025. Yount, S., Choi, S., Victorson, D., Ruo, B., Ray, D., Cella, D., Anton, S., & Hamilton, A. (2011) Brief, valid measures of dyspnea and related functional limitations in chronic obstructive pulmonary disease (COPD). Value in Health 2011; 14: 307-315. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Dyspnea Functional Assessment of Chronic Illness Therapy - Dyspnea-10 item LEARN MORE PROMIS SF v1.0 – Dyspnea Severity 10a Patient-Reported Outcomes Measurement Information System Short Form - Dyspnea Severity 10a LEARN MORE PROMIS SF v1.0 – Dyspnea Severity 5b Patient-Reported Outcomes Measurement Information System Short Form - Dyspnea Severity 5b LEARN MORE

BACK FANLTC Scoring Downloads Download DOC

BACK DVT-LSI Scoring Downloads Download PDF

BACK FACIT-CNI-NTX Scoring Downloads Download DOC

PRAI Patient-Reported Arthralgia Inventory For patients with arthralgia LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Developed in conjunction with Vanderbilt University, the 16-item Patient-Reported Arthralgia Inventory (PRAI) was designed to measure arthralgia severity in 16 joints in the context of a longitudinal cohort study to assess aromatase inhibitor-associated arthralgia in breast cancer survivors and arthralgia in postmenopausal women without breast cancer. MEASURE NAME: Patient-Reported Arthralgia Inventory (PRAI) VERSION: 2 NUMBER OF ITEMS: 16 PATIENT POPULATION: Patients 18 years and older with arthralgia RECALL PERIOD: Past 7 days RESPONSE SCALE: 10 point rating scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: None TIME FOR COMPLETION: Not available SCORING: Manual scoring template RELATED MEASURES: FACT-G , FACT-G7 , FACT-BP DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PRAI can be obtained when licensing the measure. Users are not permitted to translate the PRAI without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the PRAI. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Castel LD, Wallston KA, Saville BR, Alvarez JR, Shields BD, Feurer ID, Cella D. Validity and reliability of the Patient-Reported Arthralgia Inventory: validation of a newly-developed survey instrument to measure arthralgia. Patient Relat Outcome Meas. 2015 Jul 28;6:205-14. doi: 10.2147/PROM.S47997. PMID: 26251635; PMCID: PMC4524452. LICENSE THIS MEASURE Related Measures Related Measures FACT-G Functional Assessment of Cancer Therapy - General LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy – General – 7 Item Version LEARN MORE FACT-BP Functional Assessment of Cancer Therapy - Bone Pain LEARN MORE

BACK FAHI Scoring Downloads Download DOC

BACK FACT-CSI Scoring Downloads Download DOC - FACT-CSI Download DOC - FACT-GINET Download DOC - FACT-LNET Download DOC - FACT-PNET

BACK peds FAACT English Downloads Download PDF - Child Download DOC - Child Download PDF - Parent of Child Download DOC - Parent of Child Download PDF - Adolescent Download DOC - Adolescent Download PDF - Parent of Adolescent Download DOC - Parent of Adolescent